Bellerophon Therapeutics (NASDAQ:BLPH) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report report published on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

NASDAQ:BLPH opened at $0.05 on Friday. The firm’s fifty day simple moving average is $0.06 and its 200 day simple moving average is $0.06. The stock has a market cap of $623,730.00, a P/E ratio of -0.06 and a beta of 0.73. Bellerophon Therapeutics has a twelve month low of $0.03 and a twelve month high of $0.52.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.